Evercore ISI initiated coverage on Metsera
$MTSR
Biotechnology: Pharmaceutical Preparations
Health Care
Evercore ISI initiated coverage of Metsera with a rating of Outperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2025 | $56.00 | Buy | Guggenheim |
| 2/25/2025 | $38.00 | Buy | BofA Securities |
| 2/25/2025 | Outperform | Evercore ISI |
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
4 - Metsera, Inc. (0002040807) (Issuer)
Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00
BofA Securities initiated coverage of Metsera with a rating of Buy and set a new price target of $38.00
Evercore ISI initiated coverage of Metsera with a rating of Outperform
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025MET-097o, an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224o is on track, with four-week data for selected lead expected in late 2025 $588 million cash and cash equivalents support runway into 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical compa
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Bank of America 2025 Global Healthcare Conference on Wednesday, May 14 at 2:20 - 2:35 P.M. PDT (5:20 – 5:35 P.M. EDT). A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1 Oral formulation optimization study on track to support initiation of clinical trials for MET-224o and MET097o, with MET-224o data expected in late 2025 Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027 NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medici
SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)
10-Q - Metsera, Inc. (0002040807) (Filer)
8-K - Metsera, Inc. (0002040807) (Filer)